The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer

Oncotarget

Volumn 7, Issue 47, 2016, Pages 77607-77621

  Gujam, Fadia J A ^a,b   McMillan, Donald C ^a   Edwards, Joanne ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Breast cancer; STAT1; STAT3; Tumour microenvironment and survival

Indexed keywords

STAT1 PROTEIN; STAT3 PROTEIN; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SPECIFIC SURVIVAL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; NECROSIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT; BREAST TUMOR; CELL NUCLEUS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PHOSPHORYLATION; SURVIVAL ANALYSIS; TUMOR INVASION;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHORYLATION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84998546897     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12730     Document Type: Article

References (61)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN2012. International journal of cancer. 2015; 5: E359-86.
2. Hanahan D, and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144: 646-674.
3. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014; 16: 717-27.
4. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007; 282:20059-63.
5. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity. 2012; 36:503-14.
6. Regis G, Pensa S, Boselli D, Novelli F, Poli V. Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol. 2008; 19:351-9.
7. Darnell JE Jr. STATs and gene regulation. Science (Wash. DC). 1997; 277: 1630-1635.
8. Buettner R, Mora LB, Jove R. Molecular Targets for Therapeutic Intervention Activated STAT Signaling in Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention. Clin Cancer Res. 2002; 8: 945-954.
9. Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis: A matter of balance. Jak-Stat. 2012; 1: 65-72.
10. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000; 19: 6613-6626.
11. Chapman RS, Lourenco P, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ. The role of Stat3 in apoptosis and mammary gland involution. Conditional deletion of Stat3. Adv. Exp. Med. Biol. 2000; 480: 129-138.
12. Sutherland KD, Vaillant F, Alexander WS, Wintermantel TM, Forrest NC, Holroyd SL, McManus EJ, Schutz G, Watson CJ, Chodosh LA, Lindeman GJ. c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. EMBO J. 2006; 25: 5805-5815.
13. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res. 2002; 8: 3065-3074.
14. Magkou C, Giannopoulou I, Theohari I, Fytou A, Rafailidis P, Nomikoset A, Papadimitriou C, Nakopoulou L. Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathol 2012; 60: 1125-1132.
15. Sheen-Chen SM, Huang CC, Tang RP, Yang CH, Chou FF, Eng HL. Signal transducer and activator of transcription 1 in breast cancer: analysis with tissue microarray. Anticancer Res. 2007; 27: 2481-2486.
16. Huang R, Faratian D, Sims AH, Wilson D, Thomas JS, Harrison DJ, Langdon SP. Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer. PLoS ONE. 2014; 9: e94226.
17. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut M Allasia C, Bonnier P, Garcia S. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer. 2009;124: 2124-2134.
18. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res. 2003; 9: 594-600.
19. Sato T, Neilson LM, Peck AR, Tran TH, Witkiewicz A, Hyslop T, Nevalainen MT, Sauter G, Rui H. Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res. 2011; 1: 347-355.
20. Sheen-Chen SM, Huang CC, Tang RP, Chou FF, Eng HL. Prognostic value of signal transducers and activators of transcription 3 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2286-2290.
21. Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer. 2006; 13: 885-893.
22. Aleskandarany MA, Agarwal D, Negm OH, Ball G, Elmouna A, Ashankyty I, Nuglozeh E, Fazaludeen MF, Diez-Rodriguez M, Nolan CC, Tighe PJ. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. Breast cancer research and treatment. 2016; 156:9-20.
23. Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, Rottenberg Y, Hamburger T, Mali B, Peretz T. Tissue microarray-based study of patients with lymph nodepositive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin Transl Oncol. 2012; 14: 232-236.
24. Sonnenblick A, Uziely B, Nechushtan H, Kadouri L, Galun E, Axelrod JH, Katz D, Daum H, Hamnurger T, Maly B, Allweis TM, Peretz T. Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2013;138:407-13.
25. Lin N, Gelman R, Brock J, Bardia A, Mayer EL, Overmoyer B, Wang V, Iannone M, Krop IE, Polyak K, Winer EP. Phase II study of ruxolitinib in patients with pStat3+ breast cancer. J Clin Oncol. 2013; 31: abstr TPS1134.
26. Koromilas AE, Sexl V. The tumor suppressor function of STAT1 in breast cancer. Jak-Stat. 2013; 2: e23353.
27. Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med. 2002; 2: 381-392.
28. Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal. 2007; 19:454-65.
29. Schneckenleithner C, Bago-Horvath Z, Dolznig H, Neugebauer N, Kollmann K, Kolbe T, Decker T, Kerjaschki D, Wagner KU, Müller M, Stoiber D. Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget. 2011; 2:1043-54. doi: 10.18632/oncotarget.371.
30. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ. STAT1-deficient mice spontaneously develop estrogen receptor a-positive luminal mammary carcinomas. Breast Cancer Res. 2012; 14: R16.
31. Ecker A, Simma O, Hoelbl A, Kenner L, Beug H, Moriggl R, Sexl V. The dark and the bright side of Stat3: protooncogene and tumor-suppressor. Front Biosci. 2009;14:2944-2958.
32. Hughes K, Wickenden JA, Allen JE, Watson CJ. Conditional deletion of Stat3 in mammary epithelium impairs the acute phase response and modulates immune cell numbers during post-lactational regression. Journal of Pathology. 2012; 227: 106-117.
33. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, DePinho RA, Bonni A. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 2008; 22: 449-462.
34. Dien J, Amin HM, Chiu N, Wong W, Frantz C, Chiu B, Mackey JR, Lai R. Signal transducers and activators of transcription-3 upregulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol. 2006; 169: 633-642.
35. Kennedy AM, Shogren KL, Zhang M, Turner RT, Spelsberg TC, Maran A. 17β-Estradiol dependent activation of signal transducer and activator of transcription-1 in human fetal osteoblasts is dependent on Src kinase activity. Endocrinology. 2005; 146; 201-207.
36. Silva CM, Shupnik MA. Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Molecular endocrinology. 2007; 21: 1499-512.
37. Tell RW, Horvath CM. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors. Proc Natl Acad Sci U S A. 2014;111:12787-92.
38. Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P. Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC medicine. 2015;13:177.
39. Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science translational medicine. 2016 13;8:334ra53.
40. Yu, H., Pardoll, D. and Jove, R., 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer, 9, 798-809.
41. Hiroi M, Mori K, Sakaeda Y, Shimada J, Ohmori Y. STAT1 represses hypoxia-inducible factor-1-mediated transcription. Biochem Biophys Res Commun. 2009; 387:806-10.
42. Semenza, G.L. and Wang, G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Molecular and cellular biology. 1992; 12; 5447-5454.
43. Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE, Watson CJ, Wieckowski MR. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY). 2010; 2:823-42. doi: 10.18632/aging.100232.
44. Harris AL, Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2:38-47.
45. Bromberg, J. and Darnell, J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19.
46. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell cycle. 2005; 4:1131-1133.
47. Rivat, C., De Wever, O., Bruyneel, E., Mareel, M., Gespach, C. and Attoub, S. Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes. Oncogene. 2004; 23:3317-3327.
48. Gao, L., Zhang, L., Hu, J., Li, F., Shao, Y., Zhao, D., Kalvakolanu, D.V., Kopecko, D.J., Zhao, X. and Xu, D.Q. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clinical cancer research. 2005; 11; 6333-6341.
49. Xi, S., Gooding, W.E. and Grandis, J.R. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene. 2005; 24:970-979.
50. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11:85-95.
51. Mauro C, Leow SC Anso E, Rocha S, Thotakura AK, Tornatore L, Moretti M, De Smaele E, Beg AA, Tergaonkar V, Chandel NS. NF-kB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol. 2011; 13:1272-9.
52. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC medicine. 2012 29;10:51.
53. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784-2795.
54. Mohammed ZM, Going JJ, McMillan DC, Orange C, Mallon E, Doughty JC, Edwards J. Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology. 2012; 61: 675-684.
55. Gujam FJA, Going JJ, Mohammed ZMA, Edwards J. McMillan DC. Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer. 2014a; 676.
56. Klintrup K, Makinen JM, Kauppila S, Väre PO, Melkko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ, Mäkinen MJ. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005; 41: 2645-2654.
57. Ikpatt O, Ndoma-Egba R, Collan Y. Prognostic value of necrosis in Nigerian breast cancer. Advances in Clinical Pathology. 2002; 6: 31-37.
58. Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC. The relationship between lymphocyte subsets, hormone status and clinicopathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013; 109: 1676-1684.
59. de Kruijf EM, van Nes JG, Van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triplenegative carcinoma patients. Breast Cancer Res Treat. 2011; 125: 687-696.
60. Gujam FJA, Edwards J, Mohammed ZMA, Going J, McMillan DC. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. B J Cancer. 2014b; 111:157-65.
61. Gujam FJA, McMillan DC, Mohammed ZMA Edwards J, Going J. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. B J Cancer. 2015; 113: 1066-74.